This poster explores how Next Generation Impactor (NGI) data can be coupled with an in silico pulmonary deposition model to provide deeper insight into regional and total lung deposition.
Using published NGI datasets from four inhalers, aerodynamic particle size distribution data were re-analysed with Inhalytix® to generate consistent MMAD, GSD and fine particle fraction values, and to re-construct full particle size distributions for model input. These datasets were then applied to a lung deposition model to compare predicted deposition profiles across devices.
The study highlights the limitations of relying solely on metrics such as fine particle fraction and demonstrates how combining robust APSD analysis with computational modelling can support more informed decision making in inhaled drug development.
This poster was presented in collaboration with Microsol at DDL 2024.
